At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3
In Brief
A Phase 2 clinical trial evaluating Lopinavir/ritonavir, Emtricitabine/tenofovir disoproxil fumarate, and 3 other interventions for HIV-1 Infection and Pf Subclinical Parasitemia. Completed, enrolled 52 participants across 5 sites in 3 countries.
Detailed Summary
The purpose of this study was to see if antiretroviral therapy (ART) is safe and works at getting rid of malaria in blood and to see whether one type of ART is better than another. This study may offer information for further research in looking at whether ART plays a role in the prevention and treatment of malaria.
Study Details
Timeline
Interventions
Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
Participants received one 600 mg tablet of efavirenz orally once daily.
If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.